JP2016506923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506923A5 JP2016506923A5 JP2015554285A JP2015554285A JP2016506923A5 JP 2016506923 A5 JP2016506923 A5 JP 2016506923A5 JP 2015554285 A JP2015554285 A JP 2015554285A JP 2015554285 A JP2015554285 A JP 2015554285A JP 2016506923 A5 JP2016506923 A5 JP 2016506923A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- seq
- sequence
- nucleotide identity
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 36
- 125000003729 nucleotide group Chemical group 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 26
- 239000004005 microsphere Substances 0.000 claims 13
- 108091070501 miRNA Proteins 0.000 claims 10
- 239000002679 microRNA Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 239000002243 precursor Substances 0.000 claims 5
- 108091091751 miR-17 stem-loop Proteins 0.000 claims 4
- 108091069239 miR-17-2 stem-loop Proteins 0.000 claims 4
- 108091080309 miR-483 stem-loop Proteins 0.000 claims 4
- 108091033331 miR-503 stem-loop Proteins 0.000 claims 4
- 108091038507 miR-92b stem-loop Proteins 0.000 claims 4
- 108091081014 miR-92b-1 stem-loop Proteins 0.000 claims 4
- 108091032846 miR-92b-2 stem loop Proteins 0.000 claims 4
- 108091057645 miR-15 stem-loop Proteins 0.000 claims 3
- 108091031326 miR-15b stem-loop Proteins 0.000 claims 3
- 108091027943 miR-16 stem-loop Proteins 0.000 claims 3
- 108091074057 miR-16-1 stem-loop Proteins 0.000 claims 3
- 108091049679 miR-20a stem-loop Proteins 0.000 claims 3
- 108091039792 miR-20b stem-loop Proteins 0.000 claims 3
- 108091055878 miR-20b-1 stem-loop Proteins 0.000 claims 3
- 108091027746 miR-20b-2 stem-loop Proteins 0.000 claims 3
- 108091048857 miR-24-1 stem-loop Proteins 0.000 claims 3
- 108091047483 miR-24-2 stem-loop Proteins 0.000 claims 3
- 108091074487 miR-34 stem-loop Proteins 0.000 claims 3
- 108091092493 miR-34-1 stem-loop Proteins 0.000 claims 3
- 108091059780 miR-34-2 stem-loop Proteins 0.000 claims 3
- 108091029119 miR-34a stem-loop Proteins 0.000 claims 3
- 108091079013 miR-34b Proteins 0.000 claims 3
- 108091084018 miR-34b stem-loop Proteins 0.000 claims 3
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 claims 3
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 claims 3
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 claims 3
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 claims 3
- 108091090583 miR-34c stem-loop Proteins 0.000 claims 3
- 108091082133 miR-34c-1 stem-loop Proteins 0.000 claims 3
- 108091041286 miR-374 stem-loop Proteins 0.000 claims 3
- 108091047175 miR-374a stem-loop Proteins 0.000 claims 3
- 108091048101 miR-374b stem-loop Proteins 0.000 claims 3
- 108091056144 miR-374c stem-loop Proteins 0.000 claims 3
- 108091028159 miR-92a-1 stem-loop Proteins 0.000 claims 3
- 108091025616 miR-92a-2 stem-loop Proteins 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000033774 Ventricular Remodeling Diseases 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091056204 miR-16-2 stem-loop Proteins 0.000 claims 2
- 108091087148 miR-20 stem-loop Proteins 0.000 claims 2
- 108091066984 miR-20-1 stem-loop Proteins 0.000 claims 2
- 108091076199 miR-20-2 stem-loop Proteins 0.000 claims 2
- 108091092825 miR-24 stem-loop Proteins 0.000 claims 2
- 108091032978 miR-24-3 stem-loop Proteins 0.000 claims 2
- 108091064025 miR-24-4 stem-loop Proteins 0.000 claims 2
- 108091059456 miR-92-1 stem-loop Proteins 0.000 claims 2
- 108091084336 miR-92-2 stem-loop Proteins 0.000 claims 2
- 108091034121 miR-92a stem-loop Proteins 0.000 claims 2
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- 108091032955 Bacterial small RNA Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000037429 base substitution Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305082.3A EP2759595B1 (en) | 2013-01-24 | 2013-01-24 | Composition comprising an encapsulated antagomir |
| EP13305082.3 | 2013-01-24 | ||
| PCT/IB2014/058500 WO2014115103A1 (en) | 2013-01-24 | 2014-01-23 | Composition comprising an encapsulated antagomir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506923A JP2016506923A (ja) | 2016-03-07 |
| JP2016506923A5 true JP2016506923A5 (enExample) | 2017-02-02 |
Family
ID=47683670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015554285A Pending JP2016506923A (ja) | 2013-01-24 | 2014-01-23 | カプセル化アンタゴｍｉｒを含む組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150352055A1 (enExample) |
| EP (2) | EP2759595B1 (enExample) |
| JP (1) | JP2016506923A (enExample) |
| KR (1) | KR20160018451A (enExample) |
| CN (1) | CN105229151A (enExample) |
| AU (1) | AU2014208419A1 (enExample) |
| BR (1) | BR112015017650A2 (enExample) |
| CA (1) | CA2898958A1 (enExample) |
| ES (2) | ES2606636T3 (enExample) |
| HK (1) | HK1219753A1 (enExample) |
| HU (1) | HUE032125T2 (enExample) |
| MX (1) | MX2015009323A (enExample) |
| PL (1) | PL2759595T3 (enExample) |
| RU (1) | RU2668794C2 (enExample) |
| WO (1) | WO2014115103A1 (enExample) |
| ZA (1) | ZA201505602B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6208228B2 (ja) | 2012-06-21 | 2017-10-04 | ミラゲン セラピューティクス， インコーポレイテッド | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
| EP3247716A4 (en) * | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| WO2018183127A1 (en) * | 2017-03-25 | 2018-10-04 | MiRagen Therapeutics, Inc. | Mir-92 inhibitors for treatment of heart failure |
| CN113490488A (zh) * | 2019-03-14 | 2021-10-08 | M技术株式会社 | Plga微粒子、其缓释制剂以及其制造方法 |
| CN110484537B (zh) * | 2019-09-02 | 2021-07-27 | 中国水产科学研究院淡水渔业研究中心 | 一种miR-92促进剂及其注射剂的制备方法和应用 |
| CN110804659B (zh) * | 2019-10-23 | 2023-02-03 | 华南农业大学 | 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用 |
| CN110917359A (zh) * | 2019-11-21 | 2020-03-27 | 武汉理工大学 | 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球 |
| WO2021251526A1 (ko) * | 2020-06-11 | 2021-12-16 | 주식회사 프로스테믹스 | 신규한 mirna 유사체 및 이의 용도 |
| CN111729088B (zh) * | 2020-08-21 | 2020-12-15 | 江苏申基生物科技有限公司 | 一种微小核糖核酸miR-34a偶联探针及其制备方法 |
| WO2025050037A1 (en) * | 2023-08-31 | 2025-03-06 | The Regents Of The University Of Colorado, A Body Corporate | Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383158B2 (en) * | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US8288356B2 (en) * | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
| DE102007052114B4 (de) * | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| GB0814302D0 (en) * | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
| CA2763156A1 (en) * | 2009-05-20 | 2010-11-25 | Board Of Regents, The University Of Texas System | Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure |
-
2013
- 2013-01-24 EP EP13305082.3A patent/EP2759595B1/en not_active Not-in-force
- 2013-01-24 ES ES13305082.3T patent/ES2606636T3/es active Active
- 2013-01-24 PL PL13305082T patent/PL2759595T3/pl unknown
- 2013-01-24 HU HUE13305082A patent/HUE032125T2/en unknown
-
2014
- 2014-01-23 AU AU2014208419A patent/AU2014208419A1/en not_active Abandoned
- 2014-01-23 CA CA2898958A patent/CA2898958A1/en not_active Abandoned
- 2014-01-23 RU RU2015134770A patent/RU2668794C2/ru not_active IP Right Cessation
- 2014-01-23 ES ES14706098.2T patent/ES2688160T3/es active Active
- 2014-01-23 EP EP14706098.2A patent/EP2948551B1/en not_active Not-in-force
- 2014-01-23 KR KR1020157022914A patent/KR20160018451A/ko not_active Withdrawn
- 2014-01-23 CN CN201480017728.3A patent/CN105229151A/zh active Pending
- 2014-01-23 HK HK16107653.5A patent/HK1219753A1/zh unknown
- 2014-01-23 WO PCT/IB2014/058500 patent/WO2014115103A1/en not_active Ceased
- 2014-01-23 MX MX2015009323A patent/MX2015009323A/es unknown
- 2014-01-23 BR BR112015017650A patent/BR112015017650A2/pt not_active IP Right Cessation
- 2014-01-23 US US14/763,181 patent/US20150352055A1/en not_active Abandoned
- 2014-01-23 JP JP2015554285A patent/JP2016506923A/ja active Pending
-
2015
- 2015-08-04 ZA ZA2015/05602A patent/ZA201505602B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506923A5 (enExample) | ||
| RU2015134770A (ru) | Композиция, содержащая инкапсулированный антагомир | |
| Dai et al. | Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers | |
| Rupaimoole et al. | MicroRNA therapeutics: towards a new era for the management of cancer and other diseases | |
| Sethi et al. | Regulating miRNA by natural agents as a new strategy for cancer treatment | |
| Gambari et al. | Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology | |
| McDermott et al. | The therapeutic potential of microRNAs: disease modulators and drug targets | |
| Park et al. | Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma | |
| EP3399039B1 (en) | Compounds for treatment of ischemic injury | |
| RU2011151991A (ru) | Идентификация микро-рнк, учавствующих в постинфарктном ремоделировании и сердечной недостаточности | |
| Hernando | microRNAs and cancer: role in tumorigenesis, patient classification and therapy | |
| JP2013514372A5 (enExample) | ||
| JP2015521626A5 (enExample) | ||
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| BRPI0811170B8 (pt) | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila | |
| MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
| JP2017528441A5 (enExample) | ||
| Ishimoto et al. | Current perspectives toward the identification of key players in gastric cancer micro RNA dysregulation | |
| JP2018530530A5 (enExample) | ||
| WO2013157010A1 (en) | Methods and compositions for rnai-based cancer treatment | |
| EA201590070A1 (ru) | ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15 | |
| CN108350456A (zh) | 治疗性寡核苷酸 | |
| Mocellin et al. | Oncomirs: from tumor biology to molecularly targeted anticancer strategies | |
| Karkhane et al. | Oncogenesis and tumor inhibition by microRNAs and its potential therapeutic applications: a systematic review | |
| WO2010055148A3 (en) | Dosage of oligonucleotides suitable for the treatment of tumors |